#VisualAbstract: Tisotumab Vedotin is Effective as Second- or Third-Line Therapy for Recurrent Cervical Cancer
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: chemotherapy
#VisualAbstract: Finotonlimab with chemotherapy increases overall survival in recurrent or metastatic head and neck cancer
Click here to read this study in Nature Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
#VisualAbstract: Osimertinib after Chemoradiotherapy Increases Survival in Stage III EGFR-Mutated NSCLC
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Single-Agent Trabectedin was noninferior to physician’s choice control chemotherapy in recurrent ovarian cancer
Click here to read this study in the Journal of Clinical Oncology ©2024 2 Minute Medicine, Inc. All rights reserved. No ...
Remote electronic patient reported outcomes may have limited feasibility in older patients with cancer
1. Among patients on anticancer treatment with malignancy who were 75 years of age or older, the use of remote ...
Promising results with new oncolytic virus targeted at advanced solid tumors
1. The use of recombinant L-IFN adenovirus in patients with recurrent or refractory advanced solid tumours was well tolerated with ...
#VisualAbstract: Pembrolizumab enhances progression-free survival in patients with locally advanced cervical cancer
1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly ...
Pembrolizumab enhances progression-free survival in patients with locally advanced cervical cancer
1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly ...
Gefitinib with Chemotherapy in EGFR-Mutated Lung Cancer
1. The median overall survival was 17.6 months in the gefitinib group vs 27.5 months in the gefitinib plus chemotherapy ...
#VisualAbstract: Pazopanib does not improve disease-free survival post-metastasectomy for renal cell carcinoma patients
1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma patients 2. There was a concerning trend favouring placebo ...
